FDA grants fast track status for Prima BioMed’s CVac
The company said it will work closely work with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The two parties will jointly develop and produce Fondaparinux, an anti-thrombotic agent and Travoprost and Bimatoprost, two prostaglandin derivative drugs for treating glaucoma. Capitalizing on the strengths and